Flomics Biotech conducted an extensive Freedom-To-Operate (FTO) study in collaboration with ZBM Patents, an expert external IP firm. The study analysed 246 patent families related to cfRNA-based liquid biopsy technologies and confirmed that Flomics’ approach does not infringe on existing patents, ensuring a clear path to commercialisation.
This FTO study came at the right time for Flomics, since it is a requisite for requesting strategic European funding such as the EIC Accelerator grant from the Horizon Europe programme.
Flomics acknowledges the financial support it received for this FTO-study from ACCIÓ, the Catalan Government’s agency for business competitiveness.
